Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 6/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881001 | 1.00 | NAAA (0.64) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL4875998 | 1.00 | NAAA (0.64) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL4877315 | 0.97 | — | — | |
| SCHEMBL5932476 | 0.93 | NAAA (0.57) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL2073921 | 0.90 | — | — | |
| SCHEMBL5933026 | 0.87 | MEN1 (0.57) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL5933041 | 0.87 | MEN1 (0.57) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL5932627 | 0.86 | ALDH1A1 (0.54) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL5932926 | 0.84 | MEN1 (0.54) | NAAAEPHX1TSHRCA12CA1 | |
| SCHEMBL5933115 | 0.84 | MEN1 (0.54) | NAAAEPHX1TSHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080036373-A1 | Platinum complex and light-emitting device | TAKASAGO INTERNATIONAL CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20060202197-A1 | Platinum complex and light-emitting device | TAKASAGO INTERNATIONAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080036373-A1 | Platinum complex and light-emitting device | XPA, ERCC4, UACA | NAAA 4485/4885EPHX1 4189/4885TSHR 526/4885 |
| US-20060202197-A1 | Platinum complex and light-emitting device | RAD1, RAD51, UACA | NAAA 3715/4885EPHX1 3998/4885TSHR 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.